Beike Bio-Technology
Shenzhen, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
China's leading adult stem cell therapy company developing novel cell therapies and immunotherapies for oncology and regenerative medicine applications.
OncologyImmunology
Technology Platform
Proprietary MAR (Multi-Antigen Receptor) and TriTE (Tri-specific T-cell Engager) platforms for engineered cell therapies, plus adult stem cell isolation and expansion technologies.
Opportunities
Significant growth opportunity in China's rapidly expanding cell therapy market, particularly with proprietary platforms targeting solid tumors where current CAR-T therapies have limited efficacy.
Additional opportunity in leveraging stem cell expertise for regenerative medicine applications.
Risk Factors
Regulatory uncertainty for stem cell therapies in China and internationally, intense competition in the CAR-T space, and scientific challenges in making engineered cell therapies effective against solid tumors.
Competitive Landscape
Competes with domestic Chinese CAR-T companies like JW Therapeutics and Gracell, as well as international cell therapy leaders. Differentiates through long history in stem cell research, proprietary MAR/TriTE platforms, and established academic partnerships.